Amyotrophic Lateral Sclerosis (ALS) (cont.)
IN THIS ARTICLE
Authors and Editors
Author: Fernando Dangond, MD, Director, Medical Affairs - Specialized Therapeutics, Bayer HealthCare Pharmaceuticals.
Previous authors and editors: Editors: Neil A Busis, MD, Chief, Division of Neurology, Department of Medicine, University
of Pittsburgh Medical Center - Shadyside, Clinical Associate Professor, Department of Neurology, University of Pittsburgh School of Medicine; Mary L Windle, Pharm D, Adjunct Assistant Professor,
University of Nebraska Medical Center College of Pharmacy; Pharmacy Editor, eMedicine.com, Inc; Carmel Armon, MD, MHS, MSc, Professor of
Neurology, Tufts University School of Medicine, Chief, Division of Neurology, Baystate Medical Center, Springfield, Massachusetts.
Last Editorial Review: 12/12/2007
Fernando Dangond, MD
Must Read Articles Related to Amyotrophic Lateral Sclerosis (ALS)